"Pfizer needs to overcome $17 billion in patent expirations later this decade, Bourla acknowledged. From 2024 to 2027, Pfizer expects to lose U.S. exclusivity for popular blood thinner Eliquis, immunology med Xeljanz, rare disease med Vynadaqel, plus cancer drugs Ibrance, Inlyta and Xtandi. "

https://www.fiercepharma.com/pharma/jpm23-pfi...y-ceo-says

I have a modest suggestion......